menu

QuintilesIMS Blog

Fresh ideas and insights from our experts around the globe

distribution
Brazilians flock to pharmacies: How healthcare companies can bolster sales by embracing this shifting shopper trend
DeanSummerfield
Improving healthcare in a sustainable fashion is the shared goal of delegates at the ISPOR 17th Annual European Congress , currently underway in Amsterdam. We know our healthcare systems face many challenges as we strive for the triple aim of better outcomes, higher quality care and reduced total cost. Each stakeholder has a different role to play in overcoming these challenges but one thing is clear from the sessions at the conference - collaboration will be essential to success.  Cost effectiveness has been an important factor in decision making for a number of HTA authorities in Europe including NICE. However, there are wider issues at play in terms of enabling access to innovative medicines for patients.  In the plenary session, Carin A. Uyl-de Groot, PhD, observed that...
Read More
Anke van Engen
Gaining reimbursement for new medicines is complex. First you need to generate the right evidence and second you must successfully communicate it to a wide range of organisations.  Clinical development is a global function but value communication is the responsibility of local teams requiring collaboration between market access, marketing and medical affairs. The Global or Core Value Dossier (GVD) are essential tools in the collaboration between local affiliates and Global HQ. The GVD is intended to support affiliates with national Health Technology Assessments (HTAs) and pricing and reimbursement submissions. GVDs are usually produced centrally with the intention of ensuring alignment of the value story across countries. They are typically single documents that contain all the...
Read More
MateoG
For years, the European biopharmaceutical market has been viewed as an alluring but risky destination for biopharmaceutical companies interested in conducting global clinical trials. The fragmented regulatory environment, along with cultural and language barriers, made it a challenging and often costly environment in which to run research initiatives. But that will soon change.  In the spring of 2014, the European Parliament updated its directive on clinical trials with a new regulation that is expected to streamline the approval process for studies across the EU, harmonize regulation of trials, and increase transparency around results.  Oversight and approval of clinical trials will still fall to individual country regulators. However, the European Medicines Agency (EMA) will...
Read More
PatrickJordan
The recent flurry of acquisitions and reshuffling of assets between Pfizer, Novartis, GlaxoSmithKline and Valeant Pharmaceuticals, underscores a growing move toward specialization among larger pharmaceutical companies.  This past April, Novartis agreed to acquire Glaxo's oncology business ; to sell Glaxo its vaccines line; and to sell Eli Lilly its animal health business – all multi-billion-dollar deals. And in May, German drug maker Bayer agreed to acquire Merck's consumer care segment for $14.2 billion, which will make Bayer one of the largest providers of over the counter drugs in the world.  These deals are spurred by a ‘be first or get out of the way’ business strategy that is becoming increasingly prevalent across the industry, Lilly’s chief executive officer John...
Read More
Building a Value Relationship for Improved Patient Outcomes
A few weeks ago, I enjoyed taking part in the Quintiles' webinar ‘ UK Market Access Payer Perspectives '. I was joined by Dr Junaid Bajwa, GP and board member for Greenwich CCG , to discuss the value paradox in the UK market access space. The webinar brought the concept of 'value' and ways for biopharma and local health economies to work together locally out of the theoretical and into the real world, which of course is exactly where it needs to be. The goal of overlapping values Although we are all talking about aligning our values, it is important to be realistic. In an ideal world, industry and the NHS would be perfectly in sync, but in reality, that simply won't always be possible. It would be naive to think that commercial drivers and local care needs will always be...
Read More
Building a Value Relationship for Improved Patient Outcomes
A few weeks ago, I enjoyed taking part in the Quintiles' webinar ‘ UK Market Access Payer Perspectives '. I was joined by Dr Junaid Bajwa, GP and board member for Greenwich CCG , to discuss the value paradox in the UK market access space. The webinar brought the concept of 'value' and ways for biopharma and local health economies to work together locally out of the theoretical and into the real world, which of course is exactly where it needs to be. The goal of overlapping values Although we are all talking about aligning our values, it is important to be realistic. In an ideal world, industry and the NHS would be perfectly in sync, but in reality, that simply won't always be possible. It would be naive to think that commercial drivers and local care needs will always be...
Read More
BrianKelly
Economic pressures are changing the face of the healthcare industry. Along with proving that a new treatment options is safe and effective, biopharmaceutical companies also have to show that it is fiscally attractive to patients, providers and payers. If they fail to meet this cost/value benefit equation, payers won’t cover it and providers won’t subscribe it because patients won’t be able to afford it.  We are already seeing this trend in many counties, where medications are only paid for when their relative value is proven to be worth the price. And the same is beginning to occur in the U.S. as biopharma companies struggle to prove the economic benefits of their drugs.  To do this, biopharma companies must factor fiscal considerations of target populations into the business...
Read More
PaulSutton
Last month, I was proud to be part of the eye4pharma Value Added Services Summit in London, which provided a forum for exploring the key issues in today's market access landscape. Structuring for value   Every stakeholder – from payers and providers, to biopharma and market access specialists like ourselves – clearly understand the importance of value. How they define it is something we've covered in an earlier blog , so instead, I will cover where the effort in market access should be focused.  One of the key ideas that came out of the conference was that biopharma needs to make space for developing value-added services. We heard from a number of companies about the work they have done to develop these kinds of services. It was interesting to hear that they have created a bit...
Read More
RobinHuff
Children suffering with pediatric type 2 diabetes need more treatment options that have been tailored specifically for them. There is currently only one oral medication on the market, metformin, that has been studied in children formally. Other treatments are either not prescribed to children or are given to them based solely on studies in adults, leaving doctors to make their best guess at an appropriate dose.  We need to do better. Pediatric type 2 diabetes is a growing healthcare issue and we need to involve more children in type 2 diabetes clinical research.  Admittedly, such research can be complicated. It is difficult to recruit children for almost any type of clinical study, and pediatric type 2 diabetes is particularly challenging. While this disease is a growing...
Read More
RobinHuff
Children suffering with pediatric type 2 diabetes need more treatment options that have been tailored specifically for them. There is currently only one oral medication on the market, metformin, that has been studied in children formally. Other treatments are either not prescribed to children or are given to them based solely on studies in adults, leaving doctors to make their best guess at an appropriate dose.  We need to do better. Pediatric type 2 diabetes is a growing healthcare issue and we need to involve more children in type 2 diabetes clinical research.  Admittedly, such research can be complicated. It is difficult to recruit children for almost any type of clinical study, and pediatric type 2 diabetes is particularly challenging. While this disease is a growing problem,...
Read More